University of Illinois at Chicago

UIC clinical trials investigate COVID-19 treatments

Trials study Ebola, rheumatoid arthritis drugs in hospitalized patients

Newswise — The University of Illinois at Chicago is participating in two clinical trials for COVID-19 treatments.

COVID-19 is caused by a highly contagious virus called SARS-CoV-2 that results in acute lung injury and respiratory distress. There are currently no treatments for COVID-19.

In one trial, launched this week, a team from UIC is studying a drug previously approved by the U.S. Food and Drug Administration for treating rheumatoid arthritis. The drug is called sarilumab.

“Sarilumab targets cytokines, or small proteins, that are also seen in patients hospitalized with COVID-19,” said Dr. Jerry Krishnan, UIC professor of medicine and principal investigator of the study. 

The study includes investigators with expertise in pulmonary/critical care medicine, internal medicine, emergency medicine, pharmacy, nursing and human-centered design.

“This highly contagious virus carries unacceptably high morbidity and mortality because we do not have any evidence-based therapeutic options beyond supportive care — this study may change that,” Krishnan said. “Randomized clinical trials in which subjects are assigned to either receive the investigational treatment or an inactive treatment — called a placebo — are the gold standard to understanding the harms and benefits of new interventions.”

In the sarilumab study, hospitalized patients with COVID-19 who participate in the study will be randomized to one of three groups: sarilumab 200 mg, sarilumab 400 mg, or placebo, as a single IV infusion.

“Because of the life-threatening nature of COVID-19 among hospitalized patients, the study was designed to offer most study participants sarilumab; only 1 in 5 participants will be randomized to the placebo group,” Krishnan said.

Krishnan said the placebo group is needed to help us understand the harms and benefits of two doses of sarilumab compared with what would have happened without sarilumab.

The adaptive phase 2/phase 3 sarilumab study is sponsored by Regeneron Pharmaceuticals as part of a public-private partnership with the U.S. Department of Health and Human Services, the U.S. Office of the Assistant Secretary for Preparedness and Response, and the U.S. Biomedical Advanced Research and Development Authority.

In another trial, launched last week, UIC researchers are investigating an antiviral drug previously studied as a treatment for Ebola in hospitalized patients with COVID-19. The drug is called remdesivir and the trial is funded by the National Institutes of Health. 

In a news release, the NIH said remdesivir “has shown promise in animal models for treating Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS), which are caused by other coronaviruses.”

UIC principal investigator and professor of medicine Dr. Richard Novak said, “We urgently need safe and effective treatments for COVID-19 and, through this trial, we hope to learn if remdesivir is beneficial for patients with COVID-19.

“It’s far too early to know if there will be a clinical benefit, but these kinds of trials are critical in the search for treatments.”

The remdesivir study is a phase 3 clinical trial, and UIC is one of 75 centers in the nation participating in the trial. 

For both studies, research participants will be enrolled through the University of Illinois Hospital.  

Filters close

Showing results

110 of 3409
Newswise: Last-resort life support option helped majority of critically ill COVID-19 patients survive, global study shows
24-Sep-2020 3:20 PM EDT
Last-resort life support option helped majority of critically ill COVID-19 patients survive, global study shows
Michigan Medicine - University of Michigan

It saved lives in past epidemics of lung-damaging viruses. Now, the life-support option known as ECMO appears to be doing the same for many of the critically ill COVID-19 patients who receive it. Patients in a new international study faced a staggeringly high risk of death, as ventilators failed to support their lungs. But after they were placed on ECMO, their actual death rate was less than 40%.

Released: 25-Sep-2020 5:05 PM EDT
Case Western Reserve University researchers to examine how COVID-19 ravaged America’s nursing homes
Case Western Reserve University

Within a few months, federal officials reported that one of every five nursing homes had experienced a death from the novel coronavirus. Not long after, several media outlets published independent analysis finding that an estimated 40% of the fatalities related to COVID-19 took place in nursing homes. Rather than surrender to the terrifying trend, Case Western Reserve researchers saw an opportunity to help.

Released: 25-Sep-2020 4:15 PM EDT
Faced with pandemic shortages, researchers combine heat and humidity to disinfect N95 masks for reuse
SLAC National Accelerator Laboratory

They found that gently heating N95 masks in high relative humidity could inactivate SARS-CoV-2 virus trapped within the masks, without degrading the masks’ performance.

Released: 25-Sep-2020 3:30 PM EDT
Team assessing if dual-antibody injection prevents COVID-19 illness
University of Texas Health Science Center at Houston

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston (UTHealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.

Released: 25-Sep-2020 2:30 PM EDT
Yes, Wisconsin Republicans have the power to overturn the extended mask mandate order by Governor Evers

Republicans have the legal power to reverse the order by Wisconsin Governor Tony Evers that extends the mask mandate.

Released: 25-Sep-2020 1:55 PM EDT
How do Americans view the virus? Anthropology professor examines attitudes of COVID
Northern Arizona University

In her ongoing research about Americans' responses to the COVID-19 pandemic, Northern Arizona University anthropology professor Lisa Hardy and her collaborators have talked to dozens of people.

Released: 25-Sep-2020 12:55 PM EDT
During pandemic, racism puts additional stress on Asian Americans
Massachusetts General Hospital

Many people are feeling anxious during these uncertain times as they navigate the risks associated with COVID-19 and experience the tension from physical distancing or isolation for what can seem like an eternity.

Released: 25-Sep-2020 12:55 PM EDT
COVID-19 shapes political approval ratings
University of North Carolina at Chapel Hill

Approval ratings of political leaders surged in the early days of the COVID-19 pandemic, according to a new study published in the Proceedings of the National Academy of Sciences.

Released: 25-Sep-2020 12:40 PM EDT
ASU Researchers Receive $6m State Contract to Develop Rapid, 20-Minute Covid-19 Saliva Test
Arizona State University (ASU)

As the world manages through the coronavirus pandemic, Arizona State University continues its work to discover and develop easier and more widespread COVID-19 testing to assist in managing the virus.

Released: 25-Sep-2020 11:55 AM EDT
Scholars untangle marketing's complex role in understanding political activities
American Marketing Association (AMA)

As 2020 began, many pundits predicted a politically charged year, but few predicted that it would include a global pandemic overtaxing healthcare resources, strained U.S. race relations resulting in mass demonstrations across the globe, devastating fires consuming massive swaths of the United States, and a catastrophic global economic downturn.

Showing results

110 of 3409